Last reviewed · How we verify
TBI-1301
TBI-1301 is a monoclonal antibody targeting CD47.
TBI-1301 is a monoclonal antibody targeting CD47. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | TBI-1301 |
|---|---|
| Also known as | NY-ESO-1-specific TCR gene transduced T lymphocytes |
| Sponsor | Takara Bio Inc. |
| Drug class | CD47 antibody |
| Target | CD47 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CD47 is a protein that inhibits phagocytosis, and blocking it can stimulate the immune system to attack cancer cells. TBI-1301 works by binding to CD47 and preventing it from interacting with its receptor, SIRPα, on the surface of immune cells.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Anemia
- Thrombocytopenia
Key clinical trials
- Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma (PHASE3)
- A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer (PHASE1)
- Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors (PHASE1)
- Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma (PHASE1, PHASE2)
- Investigator Initiated Phase 1 Study of TBI-1301 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TBI-1301 CI brief — competitive landscape report
- TBI-1301 updates RSS · CI watch RSS
- Takara Bio Inc. portfolio CI